SPY415.87+4.42 1.07%
DIA340.44+2.91 0.86%
IXIC14,038.76+180.92 1.31%

Fulgent Genetics Awarded Contract from CDC to Study Variants of COVID-19 Virus

Fulgent Genetics, Inc. (NASDAQ:FLGT) ("Fulgent Genetics" or the "Company"), a technology company providing comprehensive testing solutions through its scalable platform, today announced that the U.S.

· 03/15/2021 16:07

Fulgent Genetics, Inc. (NASDAQ:FLGT) ("Fulgent Genetics" or the "Company"), a technology company providing comprehensive testing solutions through its scalable platform, today announced that the U.S. Centers for Disease Control and Prevention ("CDC") has awarded the Company a contract to provide genomic sequencing of samples of SARS-CoV-2 on an ongoing basis, leveraging the Company's Next Generation Sequencing ("NGS") capabilities.
 

Under the agreement, Fulgent Genetics will sequence the genomes of random samples that have tested positive for SARS-CoV-2, the virus that causes COVID-19. Fulgent will leverage its NGS platform and provide sequencing data to the CDC as part of their initiative to conduct a large-scale genomic survey of the virus using random samples from across the United States. Ultimately, the CDC believes this large-scale genomic survey of the virus can provide important baseline information for national and state-level virus surveillance, help define important changes in transmission, help to identify unusual or emerging variants, and ultimately improve the public health response to the virus.

Fulgent believes its position as a leading provider of COVID-19 testing solutions, combined with the Company's ability to handle large volumes of samples on its NGS platform, make the Company uniquely suited to aid the CDC in this initiative. Fulgent was selected as a partner due to its access to samples, laboratory capabilities for processing and sequencing of these samples, ability to manage the significant amount of data collected, and ability to deliver data to the CDC under the strict specifications they require.

"We are pleased to be able to leverage our NGS capabilities to aid the CDC in the study of SARS-CoV-2," said Dr. Harry Gao, Chief Scientific Officer at Fulgent Genetics. "We believe that a thorough understanding of the genomic data of the virus gathered through this study will improve our collective ability to fight COVID-19 over the long term. We look forward to supporting the CDC in this ongoing initiative."